# CJC-1295 Research Findings: GH, IGF-1, Half-Life, and the Sleep Axis > CJC-1295 research findings logged from the peer-reviewed record: GH up 2- to 10-fold for 6+ days, IGF-1 for 9-11 days, a 5.8-8.1 day half-life, preserved pulsatility, and the GHRH/sleep link. The GH/IGF-1 magnitudes, the half-life, the preserved pulse rhythm, the GHRH/sleep link, and the GHRH-plus-GHRP rationale — each readout tagged to the paper that measured it. ## What the GH/IGF-1 findings show CJC-1295 research findings center on one axis: the compound raises growth hormone, and growth hormone raises IGF-1. In healthy 20- to 40-year-old men, a single subcutaneous dose (60 or 90 µg/kg) lifted basal GH approximately 7.5-fold and mean GH about 46%, with IGF-1 up roughly 45% one week later [3]. In a separate healthy-adult cohort (ages 21-61), single doses of 30 or 60 µg/kg produced dose-dependent 2- to 10-fold increases in mean plasma GH lasting six days or more and 1.5- to 3-fold increases in IGF-1 lasting nine to eleven days; after multiple doses, IGF-1 remained above baseline up to 28 days [1]. The mechanism behind those numbers is well characterized. CJC-1295 binds the GHRH receptor on anterior-pituitary somatotrophs, activating Gs/cAMP/PKA signaling that drives GH gene transcription and release; circulating GH then acts on the hepatic GH receptor via JAK2/STAT5 to produce IGF-1 [1][2]. A 2009 proteomics study added a molecular fingerprint: in eleven healthy young men, CJC-1295 shifted the serum proteome — lowering apolipoprotein A1 and a transthyretin isoform, raising an albumin fragment and immunoglobulin species — and the immunoglobulin/albumin-fragment signal tracked linearly with IGF-1, flagging candidate biomarkers of GH/IGF-1 axis activation [5]. These are magnitude-and-duration readouts, not clinical outcomes; what sustained GH/IGF-1 elevation might mean for safety — fluid retention, insulin sensitivity, the IGF-1/cancer epidemiology — is a separate question, and the [CJC-1295 side effects](/faq) covered on the FAQ are drawn from GH-axis biology rather than dedicated safety trials. ## Pulsatility is preserved under continuous stimulation A long-acting GHRH analog could in principle flatten the body's natural GH rhythm into a continuous plateau. It does not. In the healthy-men study, while basal and mean GH rose sharply, the frequency and magnitude of pulsatile GH secretion were unaltered — the natural pulse-by-pulse rhythm stayed intact under sustained CJC-1295 stimulation [3]. In tracker terms, the natural rhythm reads as still running. This matters mechanistically because pulsatile GH delivery is thought to underlie much of GH's downstream signaling, and it is one of the more consistently cited findings in the small CJC-1295 human record. ## Half-life: DAC vs no-DAC The CJC-1295 half-life is the single figure that most depends on which form you mean. For the DAC variant, the estimated half-life in healthy adults ran 5.8 to 8.1 days, with IGF-1 elevation persisting up to 28 days after multiple doses [1]. That multi-day duration comes from the covalent albumin tether: a maleimidopropionyl linker on the peptide undergoes Michael addition with the free thiol on Cys34 of circulating serum albumin, forming a peptide-albumin conjugate that clears as slowly as albumin does [2]. The no-DAC form — "Modified GRF (1-29)" — keeps the four protease-resistant substitutions but lacks the albumin handle, so it is short-acting, clearing on a minutes-to-hours timescale that reflects native GHRH(1-29) kinetics. Confusing the two is the most common error in the popular literature, and it changes the pharmacokinetics by orders of magnitude. The dedicated [CJC-1295 DAC vs no-DAC](/dac-vs-no-dac) page logs the split in full. ## CJC-1295 and ipamorelin: the GHRH + GHRP rationale CJC-1295 and ipamorelin is the most-searched pairing in this compound's orbit, and the rationale is mechanistic. CJC-1295 is a GHRH analog; ipamorelin is a growth-hormone-releasing peptide (GHRP) that acts on the ghrelin/GHS receptor — a different receptor from the GHRH receptor. Because GHRH analogs and GHRPs stimulate GH through distinct pathways, the two are a frequently studied synergy model rather than redundant agents. Ipamorelin was characterized as the first highly selective GH secretagogue, releasing GH with minimal effect on ACTH/cortisol or prolactin [4]. Supporting ipamorelin pharmacology includes PK-PD modeling in swine [8] and rescue of glucocorticoid-induced bone-formation loss in rodents [9]. The honest limit: the mechanistic case for combining a GHRH analog with a GHRP is established, but controlled human efficacy data for this specific CJC-1295/ipamorelin combination are limited. The synergy is a rationale, not a clinical outcome. ## The sleep and recovery angle on the GH axis Growth-hormone secretion is gated by sleep, and the GHRH axis sits at that gate. In normal men, GHRH administration enhanced slow-wave sleep and increased nocturnal GH secretion, directly linking GHRH-axis stimulation to sleep architecture [6]. A 2025 study mapped a neuroendocrine circuit for sleep-dependent GH release, refining how GH secretion is timed to sleep [11]. These are findings about the GH/sleep axis broadly; CJC-1295 itself has not been studied directly against sleep endpoints. The recovery framing is honest only at the level of the axis the compound acts on, not as a sleep claim for the molecule. --- A night-tracker readout of the CJC-1295 record — every GH and IGF-1 figure logged to its study like a recovery stat, the DAC-versus-no-DAC half-life kept on separate rings, and the missing human-safety data left openly blank; no clinic behind the tracker and nothing here dispensed or sold.